HOME >> MEDICINE >> NEWS
Cervical cancer A single vaccine could benefit most women

Copenhagen, Denmark: The risk of developing cervical cancer by women infected with the Human Papillomavirus (HPV) is essentially the same no matter which type of virus is involved, provided it belongs to the group of 15 or so that are currently identified as high risk, a scientist said today.

Speaking at ECCO 12 The European Cancer Conference in Copenhagen, Dr. Xavier Bosch, of the Institut Catal d'Oncologia, Barcelona, Spain, said that testing with a cocktail of the majority of high risk type virus would provide a sufficient answer for clinical guidance, and be important to the success of any future screening or vaccination programmes.

HPV is an extremely common sexually transmitted infection. In many cases the infections are harmless and go away without the need for treatment.

But persistent infection with certain types of HPV increases the risk of cervical cancer. These types can be detected in 90-100% of cases of cervical cancer, as opposed to 5-20% of controls. These types are believed to be a necessary cause of cervical cancer and this provides a strong rationale for their use in screening and for the development of anti-HPV vaccines.

"Women who are not infected persistently with one of the cancer-causing types of HPV do not develop cervical cancer", said Dr. Bosch, "and this knowledge is helping us develop effective prevention programmes."

Dr. Bosch and colleagues derived their specific risk estimates from studying a pool of evidence collected by IARC, the International Agency for Research on Cancer, based in Lyon, France. In Europe it is estimated that 65000 new cases of cervical cancer are diagnosed each year, of which 21000 eventually lead to death. HPV carriers are typically young and sexually active, and evidence suggests that males and females are equally likely to be carriers. "In Europe and North America a vaccine including HPV 16 and 18 the most common high risk types of the virus would prevent 72% of ca
'"/>

Contact: Margaret Willson
45-3252-3383
Federation of European Cancer Societies
22-Sep-2003


Page: 1 2

Related medicine news :

1. Cervical cancer treatment depends on patient age
2. Cervical cancer vaccine may lose effectiveness during ovulation
3. Cervical tissue changes may explain false negative pap smears
4. Further Evidence On The Effect Of The UK Cervical Screening Programme
5. Cervical Screening Has Reduced Incidence And Mortality From Cervical Cancer
6. Vinegar Offers Dependable Test For Cervical Cancer
7. Women Who Have Invasive Cervical Cancer Benefit From Addition Of Chemotherapy To Radiation Treatment
8. Hormonal treatment improves survival in high-risk prostate cancer patients
9. International breast cancer prevention study launches in the United States and Canada
10. Unexpected benefit seen in treating HER-2 breast cancer with new preoperative drug combo
11. Cultural and social factors influence prostate cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cervical cancer single vaccine could benefit most women

(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... According to ... been developed that changes color when subjected to an impact force that is great ... be implemented in helmets or other sporting equipment so that coaches or officials would ...
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article published August ... Association presented data showing that it is safe for pregnant women to undergo local ... had undergone local anesthesia with a group that hadn’t, researchers were able to determine ...
(Date:9/4/2015)... ... September 04, 2015 , ... On ... has effectively doubled the size of its annual health tech innovation program. Now ... digital health startups to compete for cash and prizes to advance their technologies ...
(Date:9/4/2015)... , ... September 04, 2015 , ... With TransCel from ... mouse all within Final Cut Pro X. With TransCel users have full control over ... width, background color, speed method, frame color, inner color, text, and more. With TransCel ...
(Date:9/4/2015)... ... 2015 , ... Mile High Connects today releases “First and Last Mile Connections,” ... sidewalks, bike paths, and other vital supports severely limit access to public transportation for ... dollars to expand public transit, there’s very little support for safe and convenient access ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:Missed Connections in Metro Denver Transit 2
(Date:9/4/2015)... , Sept. 4, 2015  Janssen Research & ... and Drug Administration (FDA) has accepted for Priority ... as a treatment for patients with multiple myeloma ... (PI) and an immunomodulatory agent (IMiD), or who ... therapy, including a PI and an IMiD. This ...
(Date:9/4/2015)... -- Fair Rate Funding, a lawsuit funding firm located in ... increase in lawsuit filings in connection with the blood thinning ... Philadelphia Court of Common Pleas has ... Louisiana multi---district litigation (MDL), located in ... Louisiana , the filings are also on the ...
(Date:9/4/2015)... HILL, N.C. , Sept. 4, 2015 /PRNewswire/ ... Liaisons (MSLs) and other Field-Based Medical Specialists (FBMS) ... key opinion leaders, and thought leaders in critical ... effectiveness of their field-based teams, companies are expanding ... order to align countries with corporate objectives and ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2
Cached News: